Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Arrowhead’s Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3

Ticker(s): ARWR

Who's the expert?

Name: Dr Matthew Budoff - MD

Institution: UCLA

  • Professor of Medicine and Endowed Chair of Preventive Cardiology at UCLA.
  • Treats hundreds of patients with hypertriglyceridemia, has prescribed Vascepa, and  has been in practice 25 years advancing procedures that can help doctors identify cardiac patients early and place them on a therapeutic path to prevent a heart attack.
  • Works on at least 20 active medical research trials at any given time, and has authored or co-authored over 800 research papers, seven books, and 45 book chapters. 

Interview Questions
Q1.

Please tell us about your clinical experience. How many patients do you treat with Severe Hypertriglyceridemia or Dyslipidemia? What is currently the most efficient treatment in each indication ?

Added By: slingshot_insights
Q2.

What’s unique about Arrowhead’s approach to cardiometabolic conditions?Can you tell us more about how targeting angiopoietin like protein 3 (ANGPTL3) works in treating dyslipidemias? Please also tell us about the mechanism of action of targeting apolipoprotein C-III (APOC3) for severe hypertriglyceridemia.

Added By: slingshot_insights
Q3.

What are your thoughts on the once every 4 months to once every 6 months dosing regimen? How convincing is the the long duration of effect of ARO-APOC3 and ARO-ANG3 to you? Can you name some other agents and mechanisms that require more frequent dosing? Would you give up on those and switch to Arrowhead’s treatment option?

Added By: slingshot_insights
Q4.

Even though there has been no drug-related discontinuations, common adverse events included headache and respiratory tract infections. How problematic is the latter one from your point of view?

Added By: slingshot_insights
Q5.

Mean maximum reductions in APOC3 at 50 mg dose was recently reported at 97% in phase ½a. Mean maximum reductions in triglycerides stood at 95% and mean maximum absolute reduction in TG: -3183 mg/dL.
How do you comment on those data points? How satisfactory are the results, comparable to what you’re used to seeing in practice?

Added By: slingshot_insights
Q6.

  • In Hypercholesterolemia patients on a stable LDL-C lowering treatment regimen including statins, with or without ezetimibe, and some receiving PCSK9 inhibitors, mean maximum reductions in ANGPTL3 of 79-88% and mean maximum reductions in LDL-C of 39-42%.were reported.
  • Hypertriglyceridemia results were: mean maximum reductions in ANGPTL3 of 83%v+ Mean maximum reductions in TG of 79%

How likely would you be to switch your patients to Arrowhead’s treatment plan in the future, considering those results?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.